Basel, Switzerland

Alfred Zippelius

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 6.8

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2013-2023

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Alfred Zippelius

Introduction

Alfred Zippelius is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative work in immunotherapy. With a total of three patents to his name, Zippelius has focused on developing combination therapies that enhance the efficacy of cancer treatments.

Latest Patents

Zippelius's latest patents include groundbreaking work on combination therapy involving T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists. These inventions relate to the use of T cell activating bispecific antigen binding molecules in conjunction with PD-1 axis binding antagonists, specifically aimed at improving treatment outcomes for cancer patients. His research emphasizes the potential of these combination therapies to revolutionize cancer treatment.

Career Highlights

Throughout his career, Zippelius has worked with prominent organizations, including Hoffmann-La Roche Inc. and the University of Zurich. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant advancements in cancer research.

Collaborations

Zippelius has collaborated with notable colleagues such as Christian Klein and Vaios Karanikas. These partnerships have further enriched his research and development efforts in the realm of cancer therapies.

Conclusion

Alfred Zippelius's innovative work in the field of cancer treatment through his patented combination therapies showcases his dedication to improving patient outcomes. His contributions continue to influence the landscape of immunotherapy and cancer research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…